Cellevolve

Our approach is to bring clinical stage therapies through late-stage development and commercialization by partnering with innovators at academic medical centers and small biotechs around the world.

Globally, there are more than 2,000 cell therapies in development. We source the best clinical-stage programs and forge collaborations with the brightest minds in cell therapy. We are building one of the largest pipelines in the industry, encompassing diverse modalities across three therapeutics areas: hematology/oncology, CNS and viral illnesses.

Cell therapies can be more rapidly translated from concept into human studies, and the pivotal studies generally require smaller numbers of patients. We engage patients, clinicians, and regulators very early in the process, with commercialization in mind from the start. We integrate patient-centric, innovative approaches for clinical trial recruitment and retention to ensure timely data read outs. We have decades of experience in clinical development and are supported by our team of advisors providing expertise in cell therapy and clinical care.

Commercialization of cell therapies is meaningfully different compared to traditional drugs. They are, by their very nature, a bespoke therapy. Their timely production and delivery to patients requires efficient, collaborative processes that are supported by robust quality systems. Our novel Cellution™ platform is designed to address these needs. It accelerates patient access to therapy, provides real-time status updates for care teams, and enables the improvement of patient outcomes. This platform orchestrates product supply and care team support from clinical development through commercialization across a variety of cell therapy types.